arsenic trioxide has been researched along with mk-8776 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Acconcia, F; Albanesi, J; Bianchi, F; di Masi, A; Franza, M; Leone, S; Mancini, B; Pennisi, R | 1 |
1 other study(ies) available for arsenic trioxide and mk-8776
| Article | Year |
|---|---|
The clinically relevant CHK1 inhibitor MK-8776 induces the degradation of the oncogenic protein PML-RARĪ± and overcomes ATRA resistance in acute promyelocytic leukemia cells.
Topics: Arsenic Trioxide; Caspase 3; Caspases; Cell Differentiation; Humans; Leukemia, Promyelocytic, Acute; Oncogene Proteins, Fusion; Tretinoin | 2023 |